# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Swami Vivekananda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI032-SYN-TD
- Date: 1898-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anjali Thornbury-Mensah, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Review after seven months away, a week after an asthma attack. **S**

## History of present illness

Swami Vivekananda returns a week after the sick visit for a moderate asthma attack, and nine days after coming home from seven months of travel in the mountains. He finished five days of prednisone three days ago; his glucose rose to 210 to 268 mg/dL before the evening meal during the course and came back to 120 to 140 fasting within two days, without other treatment. The nurse telephoned on the second day. He has used the budesonide-formoterol inhaler two to four times a day; he has woken twice in the week with tightness, and the attacks are milder. While away he took metformin 1872 mg, losartan and atorvastatin, messaged his fasting readings (110 to 135 mg/dL), and kept his fortnightly fasts with fruit and milk. He could not find a laboratory for the three-month blood tests, so they were not done. He completed four of six video sessions for insomnia and falls asleep within about 45 minutes on most nights. The festival of the goddess is in two weeks and he intends to keep its fast. **S**

| Element | Detail |
|---|---|
| Asthma | Reliever two to four times a day; woken twice in a week; Asthma Control Test 15 |
| Prednisone and glucose | Evening glucose 210 to 268 mg/dL during the course; settled within two days |
| While away | Fasting glucose 110 to 135 mg/dL; three-month laboratory tests not done |
| Sleep | Four video sessions of cognitive behavioral therapy for insomnia; about 45 minutes to fall asleep |
| Coming fast | A festival fast in two weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Wheeze and tightness on two nights this week; cough in the mornings |
| Constitutional | Negative | Energy returning; weight 74.8 kg |
| Cardiovascular | Negative | No chest pain or ankle swelling |
| Genitourinary | Negative | No nocturia; no urinary symptoms |
| Psychiatric | Negative | Cheerful; PHQ-2 1 |

5 systems reviewed. **S**

## Current medications

- Metformin extended-release 500 mg tablets: four tablets (1872 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink **S**
- Losartan 25 mg oral tablet, one tablet daily **S**
- Atorvastatin 10 mg oral tablet, one tablet daily **S**
- Empagliflozin 10 mg oral tablet, one tablet each morning; skip it on any day of fasting without water, and stop it when unable to eat or drink **S**
- Budesonide-formoterol 160/4.5 mcg inhaler with a spacer as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one as needed, no more than 12 inhalations a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 74.8 kg; BMI 25.3 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 6.9% (high); Glucose (fasting): 124 mg/dL (high); Urine albumin-to-creatinine ratio: 34 mg/g (high); Potassium: 4.5 mmol/L; Creatinine: 0.98 mg/dL; eGFR (CKD-EPI 1893): 103 mL/min/1.73 m²; Total cholesterol: 152 mg/dL; HDL cholesterol: 39 mg/dL (low); Triglycerides: 146 mg/dL; LDL cholesterol: 84 mg/dL; FEV1 before bronchodilator: 2.95 L (low); FEV1 after bronchodilator: 3.42 L; FEV1 percent predicted before bronchodilator: 77% (low); FEV1/FVC before bronchodilator: 0.66 (low); FEV1/FVC after bronchodilator: 0.75; FeNO: 44 [ppb] (high); Asthma Control Test: 15; PHQ-2: 1. All results are synthetic.

## Change since baseline

- Glucose (fasting): 246 mg/dL (high) at baseline, 124 mg/dL (high) at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 0.98 mg/dL at this visit **S**
- eGFR (CKD-EPI 1893): 106 mL/min/1.73 m² at baseline, 103 mL/min/1.73 m² at this visit **S**
- PHQ-2: 0 at baseline, 1 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Influenza vaccine, the new season **S**
- COVID-19 mRNA vaccine, the new season's formula **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 74.8 kg, BMI 25.3; blood pressure 126/78, pulse 82; oxygen saturation 97 percent |
| Respiratory | Faint expiratory wheeze on forced expiration |
| Cardiovascular | Regular; no edema |
| Feet | Skin intact after months of walking; no calluses or sores |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma, adult onset, confirmed** (J45.40). Asthma is confirmed: FEV1/FVC 0.66 rises to 0.75 after albuterol, with a 470 mL (16 percent) rise in FEV1, and FeNO 44 ppb shows type 2 inflammation. It began on his return to the damp plains and is not controlled (Asthma Control Test 15, night waking, a recent attack needing prednisone), so he needs maintenance treatment, not only a reliever. Read with race-neutral equations, his FEV1 is 77 percent of predicted. **S**
   - GINA track 1, step 3: budesonide-formoterol one inhalation twice daily and one as needed, up to 12 a day, with a spacer.
   - Written action plan; peak flow meter to set his personal best.
   - Smoke-free room; incense outside where he can.
   - Review in four to six weeks; repeat spirometry in three months.
2. **Diabetic kidney disease, G1 A2** (E11.21). Moderately increased albuminuria on three samples over eight months (46, 41 and 34 mg/g) with an eGFR of 103 confirms diabetic kidney disease, stage G1 A2. It has fallen with better glucose and losartan, but persists. An SGLT2 inhibitor protects the kidneys and the heart and lowers glucose without hypoglycemia. He agreed to start it now, with clear rules for fasting and illness. **S**
   - Empagliflozin 10 mg each morning.
   - Skip empagliflozin on any day of fasting without water, and stop it and metformin when unable to eat or drink; drink well on fruit-and-milk fast days.
   - Watch for genital itching or soreness; keep the area clean.
   - Potassium, creatinine and urine albumin in three months, then every six months.
3. **Type 2 diabetes, at target** (E11.65). A1c 6.9 percent on metformin, down from 9.4; prednisone raised his evening glucose briefly, as expected. The A1c due at three months was missed while he travelled. **S**
   - Continue metformin 1872 mg and add empagliflozin as above.
   - For the festival fast: metformin with the meal that ends the fast; empagliflozin taken on fruit-and-milk fast days but skipped on a waterless day; glucose at midday and before breaking the fast; break it if below 70 or above 300 mg/dL, or if dizzy or unwell.
   - A1c in three months.
4. **Hypertension** (I10). 126/78 on losartan; at target. **S**
   - Continue losartan 25 mg.
5. **Mixed hyperlipidemia** (E78.2). LDL 84 and triglycerides 146 on atorvastatin 10 mg; the check due six to twelve weeks after starting was missed while he travelled. **S**
   - Continue atorvastatin 10 mg; lipids yearly.
6. **Insomnia** (G47.00). Better with cognitive behavioral therapy; he wants to finish the course. **S**
   - Remaining two video sessions.
7. **Attacks of wheeze and breathlessness** (R06.2). Explained by asthma, diagnosed today; superseded. **S**
   - Problem resolved.
8. **Moderately increased albuminuria** (R80.9). Confirmed and now recorded as diabetic kidney disease. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | A1c | Quarterly until at goal and after a change in therapy | Completed today | 6.9 percent, at target |
| Laboratory | A1c three months after the change in therapy | Quarterly after a change in therapy | Deferred | Missed: due three months after the metformin dose increase, while he was travelling in the mountains, and he could not find a laboratory. No harm resulted judging by today's A1c of 6.9 percent and his monthly fasting readings of 110 to 135 mg/dL. Corrective action: a point-of-care or mail-in A1c kit and a video visit are now arranged before any journey longer than two months |
| Laboratory | Urine albumin-to-creatinine ratio, eGFR and potassium | To confirm albuminuria; then every six months at G1 A2; potassium on an ARB | Completed today | 34 mg/g, the third abnormal sample (46, 41, 34): diabetic kidney disease confirmed; eGFR 103; potassium 4.5 |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting | Deferred | Missed: due six to twelve weeks after starting atorvastatin, during his travels; done today, seven months after starting: LDL 84, triglycerides 146. No harm resulted. Corrective action: as for the A1c, testing before long journeys is now planned |
| Examination | Blood pressure, weight and BMI | Every visit | Completed today | 126/78; weight 74.8 kg, BMI 25.3 |
| Examination | Foot examination | Yearly; inspection after long walking | Completed today | Intact; no calluses or sores |
| Medication safety | SGLT2 inhibitor safety: fasting, illness, genital infection and volume | At start and every visit | Completed today | Fasting and sick-day rules given; genital hygiene advice; blood pressure 126/78; no orthostatic symptoms |
| Medication safety | Glucose during oral corticosteroids | During any steroid course | Completed today | Evening glucose 210 to 268 mg/dL during prednisone; settled without insulin |
| Self-management | Fasting plan | Before any religious fast | Completed today | Plan for the festival fast in two weeks with empagliflozin and metformin |
| Imaging | Spirometry with bronchodilator response and FeNO | At diagnosis of asthma | Completed today | FEV1 2.95 L (77 percent) to 3.42 L (+470 mL, +16 percent); FEV1/FVC 0.66 to 0.75; FeNO 44 ppb |
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 15; woken twice this week; reliever two to four times a day |
| Self-management | Review within a week of an exacerbation | Within one to seven days after any exacerbation | Completed today | Nurse call on day two; this review on day seven |
| Examination | Inhaler technique and action plan | Every visit | Completed today | Technique correct with a spacer; written plan given |
| Survey | Depression screen | Yearly and as needed | Completed today | PHQ-2 1 |
| Self-management | Vaccinations | Yearly | Completed today | Influenza and COVID-19 for the new season; hepatitis B dose 2, delayed by his travel, completes the series |
| Self-management | Insomnia treatment | Until the course is complete | Completed today | Four of six sessions done; sleep onset about 45 minutes |

## Goal progress

- Diabetes confirmed and classified within a week. Outcome by 1898-02-16: Type 2 diabetes confirmed by A1c 9.4 percent and fasting glucose 172 mg/dL; GAD65 antibodies negative and C-peptide preserved. **S**
- A1c below 7 percent without hypoglycemia, in a way that fits his diet and fasts. Outcome by 1898-10-27: A1c 6.9 percent on metformin; no hypoglycemia; fasts kept safely. **S**
- Blood pressure below 130/80. Outcome by 1898-03-23: Home 128/80 and clinic 128/80 two weeks after starting losartan. **S**
- Albuminuria reduced and kidney function preserved. In progress; target 1899-01-26. **S**
- Falling asleep within 30 minutes on most nights. In progress; target 1898-12-08. **S**

## Medication changes

- Stopped: Budesonide-formoterol 160/4.5 mcg inhaler with a spacer, one inhalation as needed for wheeze or breathlessness, no more than 12 inhalations a day, until lung function testing **S**
- Started: Empagliflozin 10 mg oral tablet, one tablet each morning; skip it on any day of fasting without water, and stop it when unable to eat or drink **S**
- Started: Budesonide-formoterol 160/4.5 mcg inhaler with a spacer as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one as needed, no more than 12 inhalations a day **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, CKD and asthma monographs (2026), Aether Forge
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- Hassanein M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract 2022;185:109185 (PMID 35016991) (2021), International Diabetes Federation and the Diabetes and Ramadan International Alliance
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society

## Follow-up

- Asthma review in four to six weeks. Diabetes and kidney review with A1c, potassium, creatinine and urine albumin in three months. Call during the festival fast if glucose is below 70 or above 300 mg/dL. Next preventive visit in the spring. **S**

